J
Josep M. Llovet
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 432
Citations - 101144
Josep M. Llovet is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Hepatocellular carcinoma & Sorafenib. The author has an hindex of 116, co-authored 399 publications receiving 83871 citations. Previous affiliations of Josep M. Llovet include Spanish National Research Council & Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle,Alejandro Forner,Josep M. Llovet,Vincenzo Mazzaferro,Fabio Piscaglia,Jean-Luc Raoul,Peter Schirmacher,Valérie Vilgrain +7 more
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
Journal ArticleDOI
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Jordi Bruix,Morris Sherman,Josep M. Llovet,Michel Beaugrand,Riccardo Lencioni,Andrew K. Burroughs,Erik Christensen,Luigi Pagliaro,Massimo Colombo,Juan Rodés +9 more
Journal ArticleDOI
Prognosis of hepatocellular carcinoma : the bclc staging classification
TL;DR: A new staging system is proposed, the Barcelona Clinic Liver Cancer (BCLC) staging classification, that comprises four stages that select the best candidates for the best therapies currently available, based on prognostic factors obtained from studies performed years ago.
Journal ArticleDOI
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.
Josep M. Llovet,Maria Isabel Real,Xavier Montaña,Ramon Planas,Susana Coll,John J. Aponte,Carmen Ayuso,Margarita Sala,Jordi Muchart,Ricard Solà,Joan Rodés,Jordi Bruix +11 more
TL;DR: Chemoembolisation improved survival of stringently selected patients with unresectable hepatocellular carcinoma and was associated with a significantly lower rate of portal-vein invasion than conservative treatment.